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Guidelines for the management of patients with
cardiovascular disease are designed to assist
cardiologists and other physicans in their practice.
Surveys are conducted to assess whether guidelines
are followed in practice. The results of surveys on
acute coronary syndromes, coronary revascular-
isation, secondary prevention, valvular heart disease
and heart failure are presented. Comparing surveys
conducted between 1995 and 2002, a gradual im-
provement in use ofsecondary preventive therapy
is observed. Nevertheless, important deviations
from established guidelines are noted, with a
significant variation among different hospitals in
the Netherlands and in other European countries.
Measures for fiuther improvement of clinical
practice indude more rapid treatment of patients
with evolving myocardial infarction, more frequent
use of clopidogrel and glycoprotein IIb/IIIa
receptor blockers in patients with acute coronary
syndromes, more frequent use of 5-blockers in
patients with heart failure and more intense
measures to encourage patients to stop smoking.
Targets for the proportion ofpatients who might
receive specific therapies are presented. (NethHeart
J2004;12:110-6.)
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Our tools for prevention, detection, diagnosis and
treatment ofcardiovascular disease have markedly
improved in the last decades, and continue to improve.
For example, we notice a rapid evolution in the use of
biochemical markers for inflammation, thrombosis,
atherosclerosis and heart failure in addition to classical
risk factors, as well as improved and new imaging
modalities (echocardiography, MRI, multislice CT).
Furthermore, interventional cardiology is developing
rapidly, both for coronary interventions as well as for
correction of congenital and other structural heart
diseases, clinical electrophysiology, devices for
treatment of arrhythmias and cardiothoracic surgery.
Moreover, there is a rapid evolution in drug therapy
for prevention and management of atherosclerosis,
arrhythmias, hypertension, diabetes and heart failure.
The evidence for the efficacy of new, improved
therapies is often based on large-scale clinical trials.
To assist the cardiologists in clinical decision-making
in this rapidly evolving field, guidelines are established
for prevention, detection and management ofcardio-
vascular disease. These guidelines combine patho-
physiological insight, evidence from clinical trials as
well as the evolution of clinical experience as judged
by panels of experts. Cardiologists as well as other
physicians are encouraged to apply these guidelines in
their practice (figure 1). However, it is also appreciated
that management of individual patients is more
complex than simply following the available guidelines.
Individual patient characteristics may require a
personalised approach, while application ofguidelines
may also be hampered by (lack of) facilities or waiting
lists.
To assess whether guidelines are being followed in
clinical practice, and whether patients in actual practice
are properly reflected by the clinical trials on which
guidelines are often based, the Euro Heart Survey
programme and the 'Zorgprogramma ofthe Nether-
lands Heart Foundation' have been developed. At the
autumn meeting of the Netherlands Society of
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Figure 1. Guidelines reflect the state ofthe art ofclinicalpractice,
based on findings from clinical and experimental research.
Educationprogrammes (in the Netherlands CVOI) should reflect
theguidelines. Surveys ofthe actualpracticeprovide information
aboutguideline adherence, and may result in adaptation of the
guidelines as well as improved educationprogrammes.
Cardiology on 24 October 2003, the results of the
Euro Heart Survey/Zorgprogramma were presented
and discussed. Guideline-based checklists were pro-
posed, which may assist cardiologists as well as other
physicians to systematically record different aspects of
patient care. Finally, recommendations on the pro-
portion of patients requiring specific therapies have
been formulated by members of the Committee for
the Euro Heart Survey/Zorgprogramma in the
Netherlands, and the Committee for Quality Assurance
(Commissie Kwaliteit) of the Netherlands Society of
Cardiology. A summary of the recommendations is
presented in this report.
Acute coronary syndromes with ST elevation
In patients with evolving myocardial infarction (ACS
with ST elevation), reperfusion therapy is indicated if
there is a history ofsymptoms starting within 12 hours
of presentation, with ST-segment elevation or pre-
sumed new bundle branch block. The preferred
therapy is primary percutaneous coronary intervention
(PCI), ifthis can be performed by an experienced team
within 90 minutes after first medical contact. The
altemative treatment is thrombolysis, as soon as possible,
when contraindications are absent and primary PCI
cannot be performed timely by an experienced team.'
In the Euro Heart SurveyAcute Coronary Syndromes,
conducted in 2000 and 2001, 4431 patients with ST
elevation or new bundle branch block were registered.
In the Netherlands, primary PCI was offered in 11%,
thrombolysis in 54%, and 35% did not receive early
reperfusion therapy.2 Furthermore, it was apparent that
in about halfofthe patients the time interval between
arrival in hospital and reperfusion therapy exceeded
the recommendations (figure 2). In 52% of patients
Thrombolysis
i 100
X180
60
40
20
,4
-50
Recommendation
EHS
30
0 50 100 150
Time Interval (min.)
100
1 80-
Primary PCI
Guideline
EHS
60- >t55%
40-
20-
-50 0 5090 150 250
Time Interval (min.)
Figure 2. Time interval between arrival in emergencydepartment
(t=0O) and initiation of thrombolytic therapy (leftpanel) orfirst
balloon inflation (right panel). Guidelines specify initiation of
tm bolytic therapyearly, within 30minutes after hospital arrival.
This is achieved in 48% of patients. Primary PCI should be
conducted within 90 minutes after hospital arrival, which is
achieved in 55% ofpatients.
registered in the Netherlands it took more than 30
minutes after hospital arrival before thrombolytic
therapy was started, while in 45% ofthose referred for
primary PCI, the treatment delay in hospital was more
than 90 minutes. About 10% of patients received
prehospital thrombolytic therapy.
To optimise patient management it is recom-
mended that every hospital or region develops a
protocol for patients with evolving myocardial
infarction, taking into account the local infrastructure.
Main objectives should be to offer reperfusion therapy
to all patients presenting within 12 hours after symptom
onset, with ST elevation or a presumed new left bundle
branch block. If primary PCI is offered, at least 75%
ofpatients should be treated within 90 minutes (time
from hospital arrival to first balloon inflation). In
patients treated with thrombolysis the infusion should
be started within 30 minutes after hospital arrival in at
least 75% ofpatients. The checklist presented in table 1
may be used to register your hospital's performance.
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Table 1. Checklist emergency care ACS.
- ST elevation or nem LBBB? Y / N
- Time onset symptoms
- ER <> 12 hours Y/ N
- Reperfusion therapy Y / N
Why not? ........................
- Primary PCI, reason for choice ........................
Time interval: ER - primary PCI time:
- Thrombolysis, reason for choice .......................
Time interval: ER - thrombolysis time:
ill
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In patients with evolving myocardial infarction (ACS
with ST elevation) aspirin and P-blockers are re-
commended. Guidelines recommend glycoprotein
1Ib/IIIa receptor blockers for all patients undergoing
primary PCI, or a combination ofa fibrinolytic agent
with low-molecular-weight heparin in case ofthrombo-
lysis. Table 2 presents the recommended (target) and
observed use ofthese agents in the Euro Heart Survey
in the Netherlands. Indeed, aspirin and n-blockers are
used as expected, while the use of glycoprotein
IIb/IIIa receptor blockers and low-molecular-weight
heparin is less than expected. This may be an issue of
costs and limited healthcare resources.
Acute coronary syndromes without ST-segment
elevation
Management of patients with ACS without ST
elevation is recommended to include aspirin, combined
with clopidogrel, heparin (unfractionated or low-
molecular-weight) as well as a n-blocker. Coronary
angiography is recommended in patients at increased
risk of death or myocardial infarction.34 Severe risk
scores have been proposed to identify patients requiring
angioplasty and revascularisation. In patients under-
going PCI for acute coronary syndromes, GP IIb/IIIa
receptor blockers are recommended in the guidelines.
It should be appreciated, however, that the opinion
ofthe cardiologists present at the autumn meeting of
the Netherlands Society ofCardiology deviated from
this recommendation. About equal proportions
indicated that GP Ilb/IIIa receptor blockers should
be used in about 50%, in at least 75% or in almost all
patients. Table 3 compares the observed and recom-
mended use ofmedication in this group ofpatients. The
use ofaspirin, heparin and [-blockers is in the expected
range, while clopidogrel and glycoprotein IIb/IIIa
receptor blockers are underused relative to the guide-
lines. The checklist in table 2 may assist cardiologists
to record management ofpatients with acute coronary
syndromes in their practice.
Coronary revascularisation
In patients with acute coronary syndromes, coronary
revascularisation is recommended either as direct PCI
in patients with evolving myocardial infarction, or in
patients without ST elevation at increased risk ofdeath
and myocardial infarction. Different risk factors have
been identified in guidelines by the European Society
of Cardiology as well as the American organisations,
including recurrent ischaemia, elevated troponin,
haemodynamic instability, major arrhythmia (VT,VF),
early post-MI angina and diabetes.
In clinical practice, however, indications for re-
vascularisation are determined as much by availability
(in hospitals with, versus those without facilities for
PCI and cardiac surgery) as by risk assessment.
Figure 3. Proportion ofpatients receiving antithrombotic, P-blocker
or statin therapyfor secondaty prevention. Hospitals are ranked
ftvm keftto rtightfim low to high use ofmedication. Note important
variation in the use of,B-blockers and statins.
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Table 2. In-hospital medical therapy (EHS-NL).
ST elevation Observed Target
Aspirin 93% >90%
Beta-blocker (iv/orally) 86% >75%
GP llb/lila + primary PCI 72% >90%
LMWH + thrombolysis 15% >90%
Table 3. In-hospital medical therapy (EHS-NL).
Non-ST elevation Observed Target
Aspirin 91% >90%
Aspirin + clopidogrel 23% >75%
LMWH and/or UFH 91% >90%
Beta-blocker (iv/orally) 83% >75%
GP llb/lila + planned PCI 50% >75%
Table 4. Checklist in-hospital medical therapy.
All ACS patients: Prescribed If no, why not:
Aspirin Y/ N ........
Beta-blocker Y /N ........
Non-STT ACS:
Clopidogrel Y/ N ........
Heparin Y /N ........
UFH Y/ N ........
LMWH Y/ N ........
PCI: GP lIb/llia Y/ N ........
112
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After the BARI (Bypass Angioplasty Revascular-
isation Investigation) trial, CABG was recommended
and PCI was discouraged in patients with diabetes.
Indeed, in BARI, patients with diabetes had an excess
mortality after PCI compared with CABG.5 However,
the use of stents and new pharmacological inter-
ventions may improve outcome of PCI in diabetes.
Indeed, other studies such as ARTS (Arterial
Revascularisation Therapy Study), did not confirm
these observations.6 In clinical practice, the proportion
ofpatients with and without diabetes referred for PCI
or surgery is similar, according to the Euro Heart
Survey observations.
In patients undergoing coronary revascularisation
for stable angina, or after an acute coronary syndrome,
medical therapy should include cholesterol-lowering
agents, statins, and in many patients [8-blockers. We
recommend such drugs in over 90% and over 75% of
patients, respectively. Figure 3 presents the proportion
ofpatients discharged with antithrombotic therapy, P-
blockers and statins after a revascularisation in the
Netherlands. It is apparent that 5-blockers and
particularly statins are underused!
Secondary prevention, lifestyle
Patients with coronary heart disease or other athero-
sclerotic diseases should make healthy food choices
including a total fat intake <30% oftotal calories, intake
ofsaturated fatty acids and trans fatty acids <10% oftotal
fat intake, total cholesterol intake <30 mg/day and
lots of fruits, cereals and vegetables. Furthermore,
patients should refrain from smoking. Regular physical
exercise is recommended.7
Approximately 20% of patients with coronary disease
smoke, in spite ofthe evidence demonstrating that risk
for future events can be reduced by about 33% after
smoking cessation. Intervention studies clearly dem-
onstrate that intensive programmes, supported by the
use of medication, are required to attempt to modify
the behaviour ofpatients who continue to smoke after
a cardiovascular event. The creation of such stop
smoking programmes throughout the Netherlands is
encouraged. At the autumn meeting ofthe Netherlands
Society of Cardiology about 50% of cardiologists
indicated that they would be willing to prescribe
nicotine-replacement therapy or other support for
patients who wish to stop smoking. Yet, the other half
considered this not to be their task. A checklist to
record the advice given to patients with coronary
disease is presented in table 5.
Secondary prevention, medical treatment
Current guidelines recommend use of aspirin in all
patients with coronary heart disease. Clopidogrel
should be prescribed in those patients not tolerating
aspirin and in addition to aspirin for nine months in
patients after acute coronary syndromes without ST
elevation. Beta-blockers are recommended as well as
lipid-lowering therapy (statins) if total cholesterol is
greater than 4.5 mmol/l (LDL .2.5 mmol/l) in spite
of dietary measures. Since the presentation of the
guidelines, additional data have been revealed regard-
ing ACE inhibitors. In view of the consistent results
from the HOPE (Heart Outcome Prevention
Evaluation) and more recentlyEUROPA (EURopean
trial On reduction of cardiac events with Perindopril
in stable cAd) studies, we suggest thatACE inhibitors
should be considered in addition to aspirin, statins and
,B-blockers in all patients with coronary heart disease.89
Figure 4 shows the use of secondary preventive
Figure 4. Proportion ofpatients usingACE inhibitors, fl-blockers,
statinsand antiplatelet therapy in Europe and in the Netherlands
(EuroAspire II Surpey).
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Table 5. Checklist lifestyle factors at discharge.
Stop smoking Done? If no, why not:
Advice smoking cessation Y / N ........
Additional practical material Y / N ........
Advice smoking cessation intervention or multifactorial programme Y / N ........
Nicotine peplacement therapy Y / N ........
Follow-up visit planned Y / N ........
Results EUROASPIRE II * Europe, n=5556
* NL, n=357 Target
ACE inhibitors >75%
Betablockers >75%
Statins _ >90%
Antiplatelets >90%
0 20 40 60 80 100
percentage
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Figure5. Gradual improvementoftherapyfor econdaryprevention
ofcoronaty artety diseasefrom 1995 to 2002. Data are combined
fromfour surveys as indicated.
medication in the 2000 EUROASPIRE II (European
Action on Secondary Prevention by Intervention to
Reduce Events) study in the Netherlands and in other
European countries.'0"'1 In the year 2000 the targets
were not met for statins, ACE inhibitors and [3-
blockers. However, a significant improvement was
observed over a series of surveys conducted between
1995 and 2002 (figure 5). A checklist to record
medical therapy in patients with coronary heart disease
is presented in table 6.
Valvular heart disease
Interventions in patients with valvular heart disease
include mechanical prostheses, bioprostheses, homo-
grafts, valve repair (in particular for mitral insufficiency)
and percutaneous interventions for mitral stenosis.
Comparing the actual practice in the Euro Heart
Survey programme in 5001 patients with guidelines,
it is evident that overall the indications for different
types of interventions are compatible with the
guidelines.'2
Endocarditis prophylaxis is recommended in
patients with previous endocarditis, in patients with
valvular heart disease, including bicuspid aortic valve
and mitral prolapse with murmur, and in patients with
valve prostheses. In the survey it became apparent that
between 25 and 40% ofpatients undergoing dental or
other procedures did not receive endocarditis pro-
phylaxis in spite ofrecommendations.
Anticoagulation is recommended in all patients
early after valve surgery. Although not recommended,
and not registered for this purpose, low-molecular-
weight heparin is used as frequently as unfractionated
heparin. In the absence ofrandomised comparisons of
low-molecular-weight heparin and unfractionated
heparin, a registry might be created to collect data on
efficacy and safety of treatment with low-molecular-
weight heparin in patients with valvular disease.
A checklist for medical treatment in patients with
valvular disease is presented in table 7.
Heart failure
Patients with heart failure and those with asymptomatic
left ventricular dysfunction should receive different
drugs for prognostic purposes including ACE in-
hibitors and [-blockers.'3"14 Angiotensin II receptor
blockers should be prescribed in patients not tolerating
ACE inhibitors. In table 8 the use ofACE inhibitors
and [-blockers is presented in 10,701 patients enrolled
in the Euro Heart Survey on heart failure, conducted
in 2000 and 2001.5,16
There is an apparent underuse of both classes of
drugs. Furthermore, it is striking that the majority of
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Secondary prevention evolution 1995.2002
100 -
80-
60-
40
o3 Antiplatelets (incl. anticoag)
20 A Beta-blockers
O Statins
* ACE inhibitors
EuroAsp-l EuroAsp-ll ACS Revasc
(95/96) (99) (00/01) (01/02)
Table 6. Checklist medical therapy for coronary heart
disease.
Treatment Prescribed If no, why not:
Antithrombotics Y /N ........
Beta-blocker Y /N ........
Statins Y/ N ........
ACE inhibitor Y /N ........
Perforned Planned
PCI Y/ N Y/ N
CABG Y/N Y/N
Table 7. Checklist medical treatment for valvular disease.
Interventions Prescribed If no, why not:
Anticoagulation Y / N ........
ASA Y / N ........
ACE inhibitor Y / N ........
Endocarditis prophylaxis Y / N ........
Patient education Y / N ........
Table 8. ACE inhibitor/,Bblocker use in EHS-HF.
ACE inhibitors Observed Target
Use in patients with LVSD 79% >90%
.50% of target dose 51% >90%
.100% of target dose 29% >50%
Beta-blockers
Use in patients with LVSD 49% >75%
>50% of target dose 16% >90%
.100% of target dose 4% >50%
LVSD = left ventricular systolic dysfunction.
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Figure 6. Proportion ofpatients with left ventricular systolic dys-
function who receive ACE inhibitor or P-blocker therapy. Pre-
sentation as infigure 3. The large open circles represent hospitals
from the Netherlands. Note a major variation in use ofdrug of
these recommended drugs among different hospitals.
patients are not treated with the appropriate dose, as
tested in clinical trials. For both classes ofdrugs there
is a wide variation in the proportion ofpatients treated
among the different hospitals (figure 6). Management
ofheart failure, as well as other types ofcardiovascular
disease, may be improved by systematic verification
of chronic treatment using a checklist as presented
in table 9.
Guidelines versus practice
From the Euro Heart Survey/Zorgprogramma it is
evident that guidelines are not always applied in
cardiology practice. This may be due to different
reasons.
First, the physician may not be aware ofall aspects
ofthe guidelines, which refer to specific patients. This
may be improved by dedicated education programmes
(figure 1), as well as by better presentation of the
guidelines. The checklists presented in this report may
indeed help to remind physicians ofthe recommended
therapy in specific patients. Furthermore, sophisticated
computer systems are under development, which aim
to present the appropriate sections of guideline upon
request, related to the characteristics ofeach individual
patient as seen in the (outpatient) clinic.
Second, the physician may not agree with the
guideline recommendations. For example, many
cardiologists do not agree with the recommended
medication ofGPIIb/IIIa blockers in all patients with
acute coronary syndromes undergoing PCI, in spite
ofconsistent findings in a series ofrandomised trials.
Third, the guidelines may not be applicable to
certain groups ofpatients. Indeed, guidelines are often
based on 'evidence' from clinical trials, which studied
selected patient groups. In particular elderly patients,
and patients with multiple concomitant disorders are
often excluded from these trials.
Fourth, the physician may judge the recommended
therapy not appropriate for a given patient, for example
because of other concomitant disease, or intolerance
to a combination ofdrugs.
Fifth, application of guidelines may be hampered
by lack ofresources, financial or otherwise. For example,
in a few European countries statins are reimbursed
only in patients with very high cholesterol rates,
>8 mmol/l, in spite of the evidence-based recom-
mendations to prescribe these drugs in all patients with
coronary disease and a LDL cholesterol >2.5 mmol/A
(total cholesterol >4.5 mmol/l). In the Netherlands,
primary PCI is not offered to the majority ofpatients
with evolving myocardial infarction (recommended
first-choice therapy), because ofthe restricted capacity
ofPCI centres. Nevertheless, the proportion ofpatients
offered primary PCI is gradually improving.
Systematic registration of the reasons why physicians
deviate from practice guidelines will help to improve
the guidelines ifneeded, and to identify issues which
require better education or organisational changes in
the local or overall healthcare system. The Euro Heart
Survey/Zorgprogramma has been developed for this
purpose, while the checklists presented in this report
may be ofhelp in your own practice.
Comments and conclusions
The options for treatment of patients with different
types of cardiovascular disease are evolving rapidly.
Accordingly, cardiologists and other physicians must
continuously review the treatments that they apply in
their practice. This applies particularly to treatments
prescribed to reduce progression of the disease and
improve prognosis. Although patients may question
the need for such treatment, and may demand a
reduction in the amount ofmedication, combination
treatment with different drugs according to guidelines,
at the appropriate dosages as used in clinical trials,
should be considered in all patients with coronary heart
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Table 9. Checklist systematic verification chronic treatment.
Pharmacological treatment [preserved/depressed LVFJ
Prescription If no, why not:
Antithrombotics Y /N ........
ACE inhibitor/ARB Y N ........
Beta-blocker Y /N ........
Aldosterone antagonist Y /N ........
Cardiac glycosides Y /N ........
Diuretics Y N ........
Nitrates Y/ N ........
Statins (if CHD) Y N ........
ARB=angiotensin Il-receptor blocker.
CHD=coronary heart disease.
LVF=left ventricular function.
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disease, valvular heart disease and heart failure. The
checklists presented above may assist the physician to
optimise patient care.
It is appreciated that recommended treatment
might not be appropriate in some patients. It will be
particularly useful to document the reasons not to
prescribe such modes of therapy, and subsequently
discuss the validity ofthese exceptions.
The Netherlands Society of Cardiology, with
support from the Netherlands Heart Foundation, will
further develop the checklists presented above, and
propose interactive computer programmes, which may
remind cardiologists and other physicians of the
recommended actions in individual patients, and
document their response. In the meantime the quality
of the practice of cardiology can be verified in each
hospital with the following four steps:
1 Review ofthe guidelines provided by the European
Society ofCardiology and Netherlands Society for
Cardiology;
2 Formulate targets for management of patients in
that particular practice, indicating the proportion
of patients who should receive a specific therapy,
the appropriate dose levels, and for patients with
evolving myocardial infarction acceptable time
delays for treatment;
3 Register your performance by applying the
checklists above to a sample ofconsecutive patients,
for example during a four-week period;
4 Analyse the results from point 3 and formulate
improvements when appropriate. U
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